Our Vision
We want to help build a future where no one dies from skin cancer.
Skin Analytics is a healthcare company that uses a custom developed artificial intelligence algorithm, DERM AI, to create innovative skin cancer pathways. AI for skin cancer helps to deliver better patient outcomes that are sustainable for health systems globally.
Skin Analytics delivers cutting edge AI for skin cancer detection.
Why Skin Analytics
Artificial intelligence has the power to change healthcare forever.
Skin Analytics has custom developed and medically tested DERM AI to ensure that it is an accurate tool that will help find skin cancer earlier. Using DERM AI means that people needing medical help can get it sooner while also providing peace of mind to those who don’t.
We don’t just say that. We invest time and resources to conduct ground breaking research. This helps to ensure that we deliver a healthcare solution with accuracy that is equivalent to a specialist. Our research focused approach helps us work with clinicians to make a meaningful difference.
What we do
How Skin Analytics Helps
Skin Cancer Facts
Watch our CEO Neil Daly explain how using our technology can help save lives and improve healthcare pathways.
- Non melanoma skin cancer is the most common cancer in the UK.
- Melanoma is the 5th most common cancer in the UK.
- Melanoma is one of the most common types of cancer to affect 15-34 year old people
- In England 470,000 cancer specialist appointments are conducted to find 8,500 melanoma and 30,000 SCC’s
Our Awards
News and Information @ Skin Analytics
Skin Analytics response to NHS AI Code of Conduct
In July 2019 the Department of Health and Social Care and NHS England published a new code of conduct for the use of digital technology in health and care. As a company at the forefront of using AI algorithms to identify Skin Cancer, we know that AI provides...
Skin Analytics Awarded ISO 13485:2016 Certification
Skin Analytics is delighted to announce that we are now ISO 13485:2016 certified. ISO 13485:2016 is an internationally recognised quality standard for medical devices and is a pre-requisite for registration as a class II medical device under the MDR. This...
Our response to BMJ article: B2C apps not up to standard.
In February 2020, skin cancer researchers released a paper calling into question the quality of evidence behind the current crop of consumer-facing skin cancer apps. The conclusion was that the studies were poorly designed and didn’t validate the claims the companies are making about their products.